The Type 1 growth factor receptors and their ligands considered as a complex system

doi:10.1677/erc.0.0080075

HOME

QUICK SEARCH:

	Author:		Keyword(s):
Year:		Vol:		Page:

Endocrine-Related Cancer 8 (2) 75 -82 DOI: 10.1677/erc.0.0080075
Copyright © 2001 by the Society for Endocrinology

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Alert me if a correction is posted

Services

	Similar articles in this journal
	Similar articles in Web of Science
	Similar articles in PubMed
	Alert me to new issues of the journal
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via Web of Science (39)
	Citing Articles via Google Scholar

Google Scholar

	Articles by Gullick, W.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Gullick, W.

Endocrine Related Cancer, Vol 8, Issue 2, 75-82
Copyright © 2001 by Society for Endocrinology

Articles

The Type 1 growth factor receptors and their ligands considered as a complex system

WJ Gullick

The Type 1 family of growth factors and their receptors play an important role in normal development, wound healing and in diseases such as cancer. The products of the four receptor genes and the ten genes specifying ligands interact in a complex pattern. Such systems may develop emergent properties which cannot be predicted from a reductionist analysis of the interactions of individual components. New methods of determining these higher level properties are, however, being developed. These include microscopic analysis of live cells expressing fluorescently tagged ligands, receptors and second messengers which can provide positional information on components of the system. Computational simulations of the complex interactions are being developed which can help to predict the properties of the system.

This article has been cited by other articles:

A. A. Memon, S. Jakobsen, F. Dagnaes-Hansen, B. S. Sorensen, S. Keiding, and E. Nexo
Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
Cancer Res., February 1, 2009; 69(3): 873 - 878.
[Abstract] [Full Text] [PDF]

S. Donnini, F. Finetti, R. Solito, E. Terzuoli, A. Sacchetti, L. Morbidelli, P. Patrignani, and M. Ziche
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways
FASEB J, August 1, 2007; 21(10): 2418 - 2430.
[Abstract] [Full Text] [PDF]

H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson
Growth factor receptor interplay and resistance in cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51.
[Abstract] [Full Text] [PDF]

L A Bazley and W J Gullick
The epidermal growth factor receptor family
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S17 - S27.
[Abstract] [Full Text] [PDF]

H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson
Development of strategies for the use of anti-growth factor treatments
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182.
[Abstract] [Full Text] [PDF]

H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814.
[Abstract] [Full Text] [PDF]

H. S. Shin, H. J. Lee, M. Nishida, M.-S. Lee, R. Tamura, S. Yamashita, Y. Matsuzawa, I.-K. Lee, and G. Y. Koh
Betacellulin and Amphiregulin Induce Upregulation of Cyclin D1 and DNA Synthesis Activity Through Differential Signaling Pathways in Vascular Smooth Muscle Cells
Circ. Res., August 22, 2003; 93(4): 302 - 310.
[Abstract] [Full Text] [PDF]

				S. Donnini, F. Finetti, R. Solito, E. Terzuoli, A. Sacchetti, L. Morbidelli, P. Patrignani, and M. Ziche EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways FASEB J, August 1, 2007; 21(10): 2418 - 2430. [Abstract] [Full Text] [PDF]

				H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson Growth factor receptor interplay and resistance in cancer Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51. [Abstract] [Full Text] [PDF]

				L A Bazley and W J Gullick The epidermal growth factor receptor family Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S17 - S27. [Abstract] [Full Text] [PDF]

				H E Jones, J M W Gee, K M Taylor, D Barrow, H D Williams, M Rubini, and R I Nicholson Development of strategies for the use of anti-growth factor treatments Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S173 - S182. [Abstract] [Full Text] [PDF]

				H E Jones, L Goddard, J M W Gee, S Hiscox, M Rubini, D Barrow, J M Knowlden, S Williams, A E Wakeling, and R I Nicholson Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr. Relat. Cancer, December 1, 2004; 11(4): 793 - 814. [Abstract] [Full Text] [PDF]

				H. S. Shin, H. J. Lee, M. Nishida, M.-S. Lee, R. Tamura, S. Yamashita, Y. Matsuzawa, I.-K. Lee, and G. Y. Koh Betacellulin and Amphiregulin Induce Upregulation of Cyclin D1 and DNA Synthesis Activity Through Differential Signaling Pathways in Vascular Smooth Muscle Cells Circ. Res., August 22, 2003; 93(4): 302 - 310. [Abstract] [Full Text] [PDF]